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ABSTRACT
The steadily increasing availability of human embry-
onic stem (hES) cell lines has created strong
interest in applying available tools for gene transfer
in murine cells to human systems. Here we present
a method for the transduction of hES cells with
ecotropic retroviral vectors. hES cells were tran-
siently transfected with a construct carrying the
murine retrovirus receptor mCAT1. Subsequently,
the cells were exposed to replication-deficient
Moloney murine leukemia virus (MoMuLV) deriva-
tives or pseudotyped lentiviral vectors. With oncore-
troviral vectors, this procedure yields overall
transduction efficiencies of up to 20% and permits
selection of permanently transduced clones with
high frequency. Selected clones maintained expres-
sion of pluripotency-associated markers and exhib-
ited multi-germ layer differentiation both in vitro and
in vivo. HES cell-derived somatic cells including
neural progeny maintained high levels of transgene
expression. Lentiviral vectors pseudotyped with the
MoMuLV envelope could be introduced in the same
manner with efficiencies of up to 33%. Transgene
expression of lentivirally transduced hES cells
remained permanent after differentiation even with-
out selection pressure. Bypassing the regulatory
issues associated with the use of amphotropic
retroviral systems and exploiting the large pool of
existing murine vectors, this method provides a safe
and versatile tool for gene transfer and lineage
analysis in hES cells and their progeny.
INTRODUCTION
Human embryonic stem (hES) cells are derived from the
inner cell mass of the blastocyst (1,2). These cells have the
potential to proliferate indeﬁnitely in culture and to differen-
tiate into all somatic cell types. These unique properties open
attractive perspectives for regenerative medicine and basic
research. The biomedical exploitation of hES cells will lar-
gely depend on the availability of technologies for permanent
and highly controlled genetic modiﬁcation.
Retroviral transduction represents a fast and efﬁcient
method for transgene expression. Over the years, a large reper-
toire of well characterized murine retroviral vectors have been
successfully applied in animal models, covering a broad range
of applications from cell lineage analysis to gene therapy
(3–5). The rapid development of the hES cell ﬁeld has gener-
ated a need to apply this technology to human cells. To be
broadly applicable in routine laboratory work, such a strategy
should ideally permit the direct application of existing retrovi-
ral vectors to human cells without additional cloning steps or
the stringent safety precautions typically associated with the
use of amphotropic viruses (6–10) (NIH Safety Guidelines;
available from the ‘NIH Ofﬁce of Biotechnology Activities’
http://www4.od.nih.gov/oba/).
Retroviral vectors derived from the Moloney murine leuke-
mia virus (MoMuLV) have been used widely in gene therapy
with multiple already established vectors tested in humans and
mice (4,11–17). Due to their permanent and exclusive integra-
tion into dividing cells, murine oncoretroviral vectors have
become a work horse tool for the lineage analysis of stem
and progenitor cells both in vitro and in vivo (18–20). The eco-
tropic nature of these vectors (host speciﬁcity for mice and
rats) has, so far, restricted their application in human cells.
Attempts to use amphotropic (host speciﬁcity including
humans) oncoretroviral vectors for gene transfer into hES
cells or human hematopoietic stem cells were further ham-
pered by low transduction efﬁciency, which may in part be
due to the restricted expression of the corresponding retroviral
receptor in stem cells (21).To enable transduction with ecotro-
pic murine vectors, we devised a two-step protocol. In a ﬁrst
step the murine retrovirus receptor mCAT1 (22) is transiently
expressed in hES cells using the nucleofection technology. In
a second step, ecotropic MoMuLV-based vectors are used to
transduce the nucleofected hES cells. Our data show that
this paradigm permits the permanent transduction and clonal
selection of hES cells without affecting their proliferative
potential and their pluripotent properties in vitro and in vivo.
Neural progeny derived from the transduced hES cells
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upon differentiation. Overall transduction efﬁciency and sta-
bility of transgene expression can be further enhanced by
the use of ecotropic pseudotyped lentiviral vectors without
necessitating further safety precautions typically associated
with lentiviruses (6–8,23) (NIH Safety Guidelines; available




hES cells [line H9.2 (24)] were maintained on irradiated
mouse embryonic ﬁbroblasts (MEFs) at 5% CO2 in medium
containing Knockout-DMEM (KO-DMEM, Gibco), 20%
serum replacement, 1% non-essential amino acids, 1 mM
L-glutamine, 0.1 mM b-mercaptoethanol and 4 ng/ml FGF2
(all Invitrogen, Karlsruhe, Germany). The cells were passaged
in a 4 day cycle by incubating with 1 mg/ml collagenase IV
(Invitrogen, Karlsruhe, Germany) at 37 C for 45 min, main-
taining the cells in small clumps. To avoid contamination
by feeder cells in the transfection and transduction analysis,
the hES cells were cultured on matrigel (R&D Systems,
Wiesbaden, Germany) in MEF-conditioned medium for one
passage. Colonies were harvested by incubating with collage-
nase and plated onto matrigel-coated 6-well dishes.
Construction of the plasmid pCAG-mCAT1-HA
The pCAG-mCAT1-HA plasmid (7.4 kb) was constructed
by inserting a BamHI–NotI fragment from the pDNA3-
mCAT1-HA vector (22) containing the coding sequence of
mCAT1-HA into corresponding cloning sites of the vector
pTriEx-1 (gift from Frank Edenhofer). The resulting pCAG-
mCAT1-HA plasmid contained the cDNA of the murine
retrovirus receptor mCAT1 including a linked haemagglu-
tinin (HA)-tag under transcriptional control of the chicken
beta-actin promoter with the CMV early immediate enhancer
(CMV-IE enhancer).
Vector virus production and concentration
Retroviral vectors were obtained from a GP-E-86 producer
cell line (25) stably transfected with the HW3-EGFP-IRES-
neo plasmid (13). The retroviral vector producing cells
were cultured in DMEM (Invitrogen, Karlsruhe, Germany)
supplemented with 10% FCS until they reached 80% con-
ﬂuency. Unconcentrated retroviral vectors were produced
by changing the medium to feeder-conditioned hES-medium
24 h before infection. Supernatant was harvested, ﬁltered
through a 0.45 mm mesh and directly used for transduction
of mCAT1-expressing hES cells or NIH3T3 mouse
ﬁbroblasts. Prior to infection, 8 mg/ml polybrene (Sigma,
Deisenhofen, Germany) was added to the virus supernatant.
To establish concentrated retroviral vectors, virus-producing
GP + E-86 cells were cultured in DMEM + 10% FCS for
24 h. Vector virus containing supernatant was harvested
and centrifuged at 7000 r.p.m. (6 g) in a Sorvall S-34 rotor
for 12–16 h at 4 C. The supernatant was discarded and
the pellet was re-suspended in 1/15 of the original volume
of feeder-conditioned hES-medium. After ﬁltration through
a 0.45 mm mesh, 8 mg/ml polybrene (Sigma, Deisenhofen,
Germany) were added and the virus was directly used to
transduce mCAT1-expressing hES cells or NIH3T3 cells.
Transient transfection of hES cells with a mCAT1
expression construct
Cells were transfected with a construct carrying a HA-tagged
murine retroviral receptor mCAT1 (22) under control of
the CMV promoter or the CMV enhanced chicken beta-
actin promoter (CAG). For transfection, hES cells were cul-
tured on matrigel (R&D Systems, Wiesbaden, Germany) in
feeder-conditioned medium for one passage. Transfection
was performed using three different protocols: Lipofection
was performed with Fugene (Roche Diagnostics, Mannheim,
Germany) according to the manufacturers’ instructions. Elec-
troporation was performed as described elsewhere (26).
To prepare cells for nucleofection, cells were digested with
accutase II (PAA Lab., Co ¨lbe, Germany) for 10 min to obtain
small clumps of  5–10 cells. 2–3 · 10
6 cells were nucleo-
fected with 2.5 mg DNA, using Amaxa’s solution 8352 and
nucleofection program B16. A range of 750000–1000000
nucleofected cells were plated on a matrigel-coated 3.5 cm
dish in feeder-conditioned media. Transfection efﬁciencies
were measured by anti-HA immunoﬂuorescence 24 h post
transfection. Mean percentages were calculated from at
least three independent experiments.
Transduction of hES cells with oncoretroviral vectors
Transduction of hES cells was performed in 3.5 cm dishes
with 1 ml of vector virus containing supernatant or 0.75 ml
of concentrated vector virus in the presence of 8 mg/ml poly-
brene (Sigma, Deisenhofen, Germany) for 8 h. At the time of
infection the cells grew in small colonies of 10–20 cells with
an overall conﬂuency of <30%. Transduction efﬁciencies were
determined by enhanced green ﬂuorescent protein (EGFP)
immunoﬂuorescence 48 h post infection. Mean percentages
were calculated from ﬁve independent experiments.
Transduction of hES cells with pseudotyped
lentiviral vectors
Lentiviral vectors were produced by co-transfection of
293T cells with the lentiviral transfer vector pWPI (20 mg),
a lentiviral expression construct carrying the EGFP-gene
under control of the EF1-promoter (gift from Didier Trono)
or pLentiPGK-EGFP-SV40-blasticidine (20 mg), a lentiviral
expression construct based on the pLenti6/V5 expression sys-
tem (Invitrogen) where the CMV promoter was replaced by a
the phosphoglycerate kinase (PGK) promoter element (gift
from Harald Neumann), the packaging plasmid pCMV-
dR8.91 (15 mg; gift from Didier Trono) and the ecotropic
envelope plasmid pEcoEnv (5 mg) using the calcium phos-
phate transfection method. Medium was changed 16 h after
transfection and the vector virus containing supernatant was
collected 36 h later. Vector virus was concentrated by low
speed centrifugation as described above and re-suspended
in 1 ml of MEF-conditioned media. MCAT1-transfected
undifferentiated hES cells or NIH3T3 cells were exposed to
vector viruses for 8 h as described above and transduction
efﬁciencies were monitored 48 h after transduction by
EGFP expression.
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Genomic DNA was extracted from cells by lysis with SDS
and proteinase K digestion followed by isopropanol precipita-
tion. DNA was digested overnight using EcoRI and ClaI
(both NEB) restriction enzymes and separated on an agarose
gel. A unique ClaI site within the retroviral transgene and
EcoRI sites within the host genome enabled the analysis of
integration events. DNA was immobilized on a positively
charged nylon membrane (Roche Diagnostics) and probed
with a
32P-labelled EGFP fragment. After exposure to X-ray
ﬁlm bands were quantiﬁed using the AIDA software (Raytest).
In vitro differentiation
To study multi-germ layer differentiation in vitro, transduced
cells were cultured as embryoid bodies (EBs) in non-
adhesive plastic dishes in KO-DMEM (Gibco), 20% serum-
replacement, 1% non-essential amino acids and 1 mM
L-glutamine (all Invitrogen, Karlsruhe, Germany) for 4–8
weeks; 5% FCS was added in some experiments to promote
differentiation. EBs were then plated onto polyornithine-
coated glass cover slides and ﬁxed 4 days later.
Neural differentiation was performed as previously
described (27) with slight modiﬁcations. Brieﬂy, 4-day-old
EBs generated in the absence of FCS were transferred to
polyornithine-coated tissue culture dishes and propagated in
ITSFn medium (DMEM/F12 (Invitrogen, Karlsruhe, Ger-
many), 25 mg/ml insulin, 100 mg/ml transferrin, 5 ng/ml
sodium-selenite (Sigma, Deisenhofen, Germany), 2.5 mg/ml
ﬁbronectin (R&D Systems, Wiesbaden, Germany)) containing
20 ng/ml FGF2. Within 10 days, neural tube-like structures
developed in the EB outgrowth. These structures were
mechanically isolated and propagated as free-ﬂoating neuro-
spheres in N2 medium containing 10 ng/ml FGF2 for
2–8 weeks. Spheres were passaged weekly by trituration
into smaller fragments. Spheres or single cells derived thereof
were plated on poly-L-lysine/laminin-coated tissue culture
dishes and further propagated in Neurobasal medium (Invitro-
gen, Karlsruhe, Germany) supplemented with B27 (Invitro-
gen, Karlsruhe) and 10 ng/ml BDNF (R&D Systems,
Wiesbaden, Germany) for a period of 3–12 weeks.
Teratoma formation
Teratoma formation was induced by injecting into SCID-
beige mice 3 · 10
6 hES cells at passage 20 after transduction
and selection as described (28). After 9 weeks, animals were
sacriﬁced. Teratomas were ﬁxed overnight in 4% paraform-
aldehyde (PFA) and subjected it to histological examination
using hematoxylin and eosin (H&E) staining.
Bromodeoxyuridine incorporation and detection
(BrdU-assay)
hES cells cultured for one passage on matrigel were trans-
fected with the mCAT1-HA construct and subsequently sub-
jected to viral transduction as described above. Twenty or
forty hours after transduction the cells were labelled with
10 mM bromodeoxyuridine (BrdU, Sigma, Deisenhofen,
Germany)for5h.Thecellswereﬁxedwith4%PFA,permeabi-
lized in 70% ethanol for 10 min, transferred into 6 N HCL and
1% Triton X-100 (15 min, room temperature), followed by
0.1 M sodium borate (in PBS, 0,1% Triton X-100 for 30 min)
and subsequently incubated with a monoclonal antibody to
BrdU (1:33, Becton-Dickinson, Heidelberg, Germany). Sig-
nal was visualized using a rhodamine-conjugated antibody
to mouse IgG (1:100, Jackson ImmunoResearch Laborator-
ies, West Grove, PA). For quantiﬁcation, cell nuclei were
counterstained with 40,6-diamidino-2-phenylindole (DAPI,
Sigma, Deisenhofen, Germany).
Immunocytochemistry
Monolayer cultures and disaggregated EBs were ﬁxed with
4% PFA in PBS for 20 min at room temperature. Cells
were permeabilized with 0.25% Triton X-100 (Sigma,
Deisenhofen, Germany) in PBS (PAA Lab., Co ¨lbe, Germany)
for 20 min. For detection of the pluripotency markers Tra-
1-60 and Tra-1-81 no Triton X-100 was used. Blocking was
performed with 10% FCS (Invitrogen, Karlsruhe, Germany)
in PBS for 1 h. Samples were incubated with primary anti-
bodies at 4 C over night, washed twice, incubated with sec-
ondary antibody for 45 min, counterstained with DAPI and
mounted with Vectashild mounting solution (Vector Laborat-
ories). Secondary antibodies were goat-anti-mouse IgG con-
jugated to Cy3 (1:500; Dianova) and goat-anti-rabbit IgG
conjugated to FITC (1:200; Jackson Immunoresearch). Omis-
sion of the primary or secondary antibodies was used to
control for unspeciﬁc staining. Four-week-old EBs were
digested in trypsin/EDTA (Invitrogen, Karlsruhe, Germany)
for 25 min, partially dissociated in smaller fragments, plated
on polyornithine-coated chamber-slides (Nunc GmbH, Wies-
baden, Germany,) and ﬁxed after 24 h. Indirect immunoﬂuo-
rescence analysis was performed using antibodies to Tra-1-60
(1:500) and Tra-1-81 (1:500; both from Chemicon, Hofheim,
Germany), alpha-fetoprotein (AFP; 1:200), cytokeratin/Lu-5
(1:1000), epithelial membrane antigen (EMA; 1:50) desmin
(1:300) and smooth muscle actin (1:800; all DAKOCytoma-
tion, Hamburg, Germany).
Neurospheres were plated in toto or after trituration
on poly-L-lysine and laminin-coated 3.5 cm dishes and
differentiated in Neurobasal medium (Invitrogen, Karlsruhe,
Germany) supplemented with B27 (Invitrogen, Karlsruhe,
Germany) and 10 ng/ml BDNF (R&D Systems, Wiesbaden,
Germany) for 1–6 weeks before ﬁxing. Indirect immunoﬂuo-
rescence analysis was performed using antibodies to nestin
(1:200; Chemicon, Hofheim, Germany), beta-III-tubulin
(1:1500; BabCo, Covance, USA), MAP2ab (1:200; Chemi-
con, Hofheim, Germany) and GFAP (1:100; ICN Biomedi-
cals, Irvine, USA). EGFP was detected using an anti-EGFP
antibody (1:4000; Abcam, Cambridge, USA).
RESULTS
Transient transfection of hES cells with the
murine retroviral receptor mCAT1
An expression construct encoding a HA-tagged variant of the
murine retrovirus receptor mCAT1 under control of the CMV
promoter (22) or the CMV-enhanced chicken beta-actin pro-
moter(CAG)wereusedtooptimizethetransfectionconditions
for hES cells. Lipofection and conventional electroporation
yielded only moderate transfection rates. Twenty-four hours
after transfection, HA-immunoﬂuorescence was detected
in 19.3 ± 4.6% of the lipofected and 34.2 ± 6.7% of the
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improve transfection efﬁciency we explored nucleofection, a
recently developed method for enhanced electroporation
(Amaxa GmbH, Cologne, Germany). Under optimized condi-
tions we achieved transient mCAT1-HA expression in 52.1 ±
8.3% of the undifferentiated hES cells (10 independent experi-
ments; Figure 1A and B). Survival rates with Amaxa’s manu-
facture program B-16 averaged around 70% and were thus
comparable to those observed in conventional electroporation
[for further information on the nucleofection of hES cells, see
Siemen et al. (2005) (29)]. 94.4 ± 2.8% of the mCAT1-HA
expressing cells showed nuclear Oct-4 immunoﬂuorescence.
Compared to Oct-4 expression of non-transfected cells
(97 ± 1.3%), the nucleofection procedure appeared to have
no signiﬁcant effect on the pluripotent state of the cells.
Transduction of mCAT1 expressing hES
cells by ecotropic MoMuLV-vectors
In this approach, transduction of mCAT1-transfected hES
cells was performed with an ecotropic MoMuLV-derived
vector encoding the EGFP under control of the MoMuLV-
50LTR IRES-linked to a neomycin resistance gene (neoR;
Figure 1C) (13,30). Viral particles were obtained from the
supernatant of stably transfected GP+E-86 cells (25), yielding
titers of up to 4.3 · 10
7 transducing units per ml as deter-
mined by infection of NIH3T3 mouse ﬁbroblasts. Starting
24 h after transfection with the mCAT1 construct, the hES
cells were exposed to 1 ml of cell-free viral supernatant for
8 h. Forty-eight hours post transduction up to 5% of the
total cell population showed EGFP-expression. Normalized
to the proportion of mCAT1-expressing cells determined in
previous experiments, this corresponds to a calculated trans-
duction efﬁciency of  10% of the mCAT1-expressing cells.
Since the hES cells were maintained on feeder cells (MEFs),
we expect a large proportion of retroviral particles to be
adsorbed by this murine cell population. Thus, feeder-free
cultivation systems may yield even higher transduction efﬁ-
ciencies. No EGFP-positive cells were observed in untrans-
fected control populations. 93 ± 4% of EGFP-positive cells
showed nuclear staining with an antibody to the Oct4-protein
(compared to 97 ± 2.4% of the non-infected cells), conﬁrming
that the infected cells largely maintain their pluripotent state.
Concentration of viral supernatant using
slow speed centrifugation
As transduction efﬁciencies of MoMuLV-derived vectors
highly depend on viral titers we searched for efﬁcient
methods to concentrate virus-containing supernatant. Ultra-
centrifugation and subsequent re-suspension of the virus-
containing pellet in 1/10 of the original volume yielded
only an  2-fold increase in viral titer, indicating that ultra-
centrifugation is not an adequate method to concentrate eco-
tropic MoMuLV-vectors. Therefore we chose a different
protocol based on low speed centrifugation over a prolonged
period of 12–16 h at 6 g (17,31). By re-suspending the viral
pellet in 1/10 to 1/20 of the original volume, viral titers could
be increased 10- to 18-fold resulting in viral titers (MOI) of
up to 8.4 · 10
8 infectious particles per ml (as determined on
NIH3T3 mouse ﬁbroblasts).
Enhanced transduction of mCAT1 expressing hES
cells by concentrated MoMuLV vectors
To explore whether transduction efﬁciencies could be
increased by elevated viral titers, vector virus-containing
supernatant was concentrated over night, re-suspended in
1/10 of original volume and ﬁltered through a 0.45 mm
mesh. Concentrated viral vectors were directly used to trans-
duce mCAT1-transfected hES cells cultured on matrigel in
feeder conditioned media, and transduction efﬁciencies were
measured 48 h post transduction using immunoﬂuorescence.
Using this method 16.4 ± 5.9% of the total cell population
showed EGFP-expression (Figure 1D). Normalized to the pro-
portion of mCAT1-expressing cells determined in previous
experiments, this corresponds to a calculated transduction
efﬁciency of  30% of the mCAT1-expressing cells. No
EGFP-positive cells were observed in untransfected control
populations (data not shown). Furthermore, no signiﬁcant
increase in toxicity of the concentrated viral vector was
observed as judged from total cell counts and the number of
detached cells at 24–72 h after transduction. Forty-eight
hours after transduction, 89.6 ± 6.8% of the transduced cells
and 96.2 ± 2% of the non-transduced cells continued to
express Oct-4 (Figure 1E). In addition, transduced and non-
transduced cells maintained expression of the pluripotency
markers Tra-1-60 and Tra-1-81 at comparable levels. Forty-
eight hours after transduction, these markers were expressed
in 86 ± 4.6%/88 ± 8.2% of the EGFP-positive cells and
88 ± 4%/91 ± 6.2% of the non-transduced cells, respectively
(Figure 1F and G; n > 3 independent experiments). These
data indicate that the two-step transduction procedure has
no signiﬁcant inﬂuence on the pluripotent state of the cells.
Performing two rounds of transduction with freshly concen-
trated virus could not increase transduction efﬁciencies in
our hands. This could be due to rapid downregulation of the
mCAT1 receptor over time. Indeed, 48 h after transfection
only 10.2 ± 8.1% of the cells still showed mCAT1-HA expres-
sion. Furthermore, we noticed a signiﬁcant increase in cell
death upon repetitive infection. Since the calculation of trans-
duction efﬁciencies could, in principle, be biased by changes
in cell proliferation upon transduction, we performed addi-
tional BrdU incorporation studies. Twenty or forty hours
after transduction, 31 ± 6%/27 ± 3% of the EGFP-expressing
cells and 34 ± 5%/26 ± 6% of the non-transduced cells showed
BrdU immunoreactivity, respectively (data not shown), indi-
cating that extrapolation of the transduction rate is not biased
by changes in cell proliferation.
Permanently transduced clones maintain
transgene expression and pluripotency
We next asked whether this method is suitable for selecting
permanently transduced clones from low titer infections.
Unconcentrated viral vectors were used for these experiments
to enable the identiﬁcation of individual clones in a mass
culture setting. 200000 mCAT1-transfected cells were plated
in a 6-well dish containing neomycin-resistant murine embry-
onic feeder cells (MEFs). Twenty-four hours later the cells
were transduced with unconcentrated viral supernatant for
8 h. At this time about 100000 of the plated 200000 cells
could be detected using an antibody to human nuclei. Forty-
eight hours post infection G418 was added to the medium.
e120 Nucleic Acids Research, 2006, Vol. 34, No. 18 PAGE 4 OF 12Figure 1. Transduction of hES cells with murine retroviral vectors. (A) Transfection efficiencies of undifferentiated hES cells using optimized protocols for
lipofection (L), electroporation (E) and nucleofection (N) techniques. (B) mCAT1-HA expression (green) in nucleofected hES cells cultured on matrigel.
Twenty-four hours after plating, the cells show a flattened morphology typical for colonies propagated on matrigel. Nuclear expression of Oct-4 (red) reflects
their undifferentiated state. (C) Schematic illustration of the two-step protocol used for transduction of hES cells with ecotropic retroviral vectors. First cells are
nucleofected with a construct encoding the murine retrovirus receptor mCAT1. Twenty-four hours later they are transduced with a murine retroviral vector.
Transduced cultures are either analyzed for transgene expression after 48 h or subjected to selection of permanently transduced clones. The integrated provirus
expresses the EGFP transgene from the viral LTR linked to a neomycin resistance gene (neoR) by an internal ribosome entry site (IRES). (D) Forty-eight hours
after infection, 16.4 ± 5.9% of the total cell population showed EGFP-expression. Normalized to the proportion of mCAT1-expressing cells determined in (A),
this corresponds to a calculated transduction efficiency of  30% of the mCAT1-expressing cells (mean values from n ¼ 5 independent experiments).
(E–G) Transduced EGFP-positive cells continue to express the pluripotency-associated markers Oct-4 (E), Tra-1-60 (F) and Tra-1-81 (G) (all red; counterstain
DAPI). (H) Five passages after transduction, four clones were subjected to Southern analysis. A single integration of the EGFP transgene could be detected in
clones PK2, PK4 and PK7. Clone PK5 displays two bands, which could be the result of a double integration, a mixed clone population or a mutation of the vector
provirus. Restriction analysis was performed with EcoRI (for genomic DNA) and ClaI (unique site within the retroviral vector). Scale bars: B,E: 100 mm; F: 30
mm; G: 50 mm.
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tiﬁed, isolated and further expanded. The number of
selectable clones per 6-well dish ranged between 8 and 20.
Thus, the overall efﬁciency of retrieving permanently trans-
duced clones with unconcentrated retroviral vectors was
already 1–2/10000 hES cells. Whereas differences in
EGFP-expression were noted between different clones, trans-
gene expression within individual clones was quite uniform.
Visible EGFP autoﬂuorescence was observed in  25% of
the clones. Using an anti-EGFP antibody all clones showed
detectable EGFP-expression. Eight randomly picked clones
were further propagated and studied across several passages.
Without antibiotic selection all clones showed downregula-
tion of EGFP after several weeks in culture. In contrast,
homogeneous expression of the EGFP-transgene was main-
tained under G418-selection over more than 60 passages.
Transduced EGFP-positive clones continued to express
markers of pluripotency, including alkaline phosphatase,
Tra-1-60, Tra-1-81 (Figure 2A–C) and Oct-4. Upon with-
drawal of G418,  50% of the cells lost visible EGFP ﬂuores-
cence within ﬁve passages. Performing immunostainings with
an anti-EGFP antibody, EGFP-expression could still be
detected in 65.2 ± 12.2% of the cells after 4 weeks without
selection pressure. These observations suggest that the trans-
duced undifferentiated cells retain pluripotency and self-
renewal capacity during prolonged cultivation, but are
bound to loose retroviral transgene expression in the absence
of selection pressure. To conﬁrm that transgene expression
resulted from stable integration of the provirus into the host
DNA, we conducted Southern blot analyses of genomic
DNA prepared from four different clones ﬁve passages
after transduction. In all four clones we found genomic inte-
gration of the EGFP-expressing provirus. Whereas clones
PK2, PK4 and PK7 showed a single integration of the viral
transgene, clone PK5 displayed two bands, which could be
the result of a double integration, a mixed clone population
or a mutation of the vector provirus (Figure 1H). These
data indicate that the loss of EGFP expression is not due to
a loss of the transgene but may be related to transcriptional
changes such as silencing of the viral LTR.
Transgene expression is retained throughout
germ layer differentiation in vitro
We further investigated the potential of virus-transduced
cells to differentiate into derivatives of all three germ layers.
When cells were cultured in non-adhesive conditions, EB
formation was observed within 24 h. In the absence of
G418, a pronounced downregulation of EGFP expression
was noticed during the ﬁrst days of EB formation. When
6-day-old EBs were dissociated and plated, only 32 ± 8% of
the cells had retained EGFP immunoﬂuorescence. In contrast,
EBs propagated in the presence of G418 showed homogen-
eous and strong transgene expression over a period of at
least 6 weeks (Figure 2D).
We then studied whether the transduced EBs retain the
potential to differentiate into derivatives of all three germ
layers. To that end, EBs were propagated for at least
Figure 2. Following retroviral transduction, hES cells maintain transgene expression and pluripotent differentiation into derivatives of all three germ layers.
(A–C) Selected clones express the pluripotency-associated markers alkaline phosphatase (A), Tra-1-60 (B, red) and Tra-1-81 (C, red) while sustaining high levels
of EGFP-expression (green). (D) Under selective conditions, EGFP-expression is maintained in differentiating EBs for at least 6 weeks. (E–H) Differentiating
EBs show expression of cytokeratin (E), epithelial membrane antigen (F), desmin (G) and alpha-fetoprotein (H), reflecting multi-germ layer differentiation.
(I–K) Transgene expression in single cells derived from 4-week-old EBs, 4 days after plating. EGFP-positive cells co-express alpha-fetoprotein (I), smooth
muscle actin (J) and epithelial membrane antigen (K) (all red). (L) Selected clones give rise to teratomas containing various somatic tissues 9 weeks after
injection into immunodeficient SCID-beige mice. Scale bars: A-C: 200 mm; D-H: 50 mm; I-K: 20 mm; L: 200 mm.
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polyornithine-coated glass slides or embedded in parafﬁn
for sectioning and immunocytochemistry. Cells of all three
germ layers could be detected both in the outgrowth of plated
EBs and in sectioned EBs. Cells of epithelial and endodermal
differentiation expressing cytokeratin, EMA and AFP were
preferentially located in the outer cell layers of the EBs;
desmin-immunoreactive cells indicative of mesodermal dif-
ferentiation were typically located in the center of the EBs
(Figure 2E–H). Double labeling with an antibody to EGFP
revealed strong transgene expression in cells positive for
AFP, smooth muscle actin and EMA (Figure 2I–K). We fur-
ther conducted a teratoma assay using a selected clone cul-
tured for 30 passages in the presence of G418. Nine weeks
after injection of 3 · 10
6 cells, ﬁve of eight recipient mice
developed teratomas with pronounced differentiation into
multiple somatic tissues (Figure 2L).
Transgene expression is retained throughout
neural differentiation
To explore whether maintenance of transgene selection
pressure is required after lineage commitment, EBs were
plated onto polyornithine-coated cell culture dishes and
propagated in neural selection medium containing DMEM/
F12, insulin (25 mg/ml), transferrin (100 mg/ml) sodium
selenite (5 ng/ml), ﬁbronectin (2.5 mg/ml), FGF2 (20 ng/ml)
and G418 for a period of 10 days. After 7 days, G418 was
discontinued. On day 10, neural islands containing dense
neural tube-like structures were mechanically isolated and
further propagated on poly-HEMA-coated tissue culture
plates in DMEM/F12 supplemented with N2 (N2 media)
and 10 ng/ml FGF2 as free ﬂoating neurospheres as described
(27,32). Using a 100 ml pipette tip, neurospheres were disso-
ciated in weekly intervals for a total time period of up to
3 months. Throughout this time the neurospheres displayed
strong EGFP expression without evidence of transgene down-
regulation (Figure 3A).
When passage six neurospheres were dissociated and pla-
ted, 89 ± 7% of the plated cells showed immunoreactivity
for the EGFP transgene. For long-term differentiation, neuro-
spheres were plated on poly-L-lysine/laminin-coated tissue
culture plates and propagated in Neurobasal medium supple-
mented with B27 and BDNF (10 ng/ml) for a period of
3–8 weeks. A dense outgrowth of neural cells was detected
within a week after plating (Figure 3B). After 3–4 weeks,
the plated neurospheres had generated an intricate network
of neurites. Immunoﬂuorescence analysis revealed strong
expression of the neuronal marker antigens beta-III-tubulin
and MAP2ab within the neurite outgrowth (Figure 3C–E).
In addition to neurons, the outgrowth contained a smaller
fraction of GFAP immunoreactive astrocytes (Figure 3F).
Overall, 91 ± 6% of cells within the neurosphere outgrowth
retained EGFP immunoﬂuorescence.
Transduction of mCAT1 expressing hES cells by
pseudotyped lentiviral vectors
Considering the increasing use of lentiviral vectors, we
were interested in whether our two-step system could also
accommodate ecotropic pseudotyped lentiviral vectors. To
address this question we used the murine-speciﬁc ecotropic
MoMuLV-envelope as lentivirus-packaging glycoprotein.
Viral vectors were designed to express the EGFP-transgene
either under the control of the PGK promoter with a blastici-
dine resistance gene under control of a SV40 promoter
(pLentiPGK-EGFP-SV40-blasticidine) or under control of
the EF1-promoter (pWPI). With pseudotyped vectors we
obtained titers of up to 1.8 · 10
9 transducing units per ml
as determined by infection of NIH3T3 cells. Twenty-four
hours after transfection with mCAT1, hES cells were exposed
to 1 ml of cell-free viral supernatant for 8 h. Immunoﬂuores-
cence analysis performed 48 h post transduction revealed that
27.2 ± 6.5% of the pLentiPGK-EGFP-SV40-blasticidine-
transduced cells and 26.1 ± 7.2% of the pWPI-transduced
cells were EGFP-positive (Figure 4A and B). Normalized
to the proportion of mCAT1-transfected cells determined in
previous experiments, this corresponds to a calculated trans-
duction rate of  50% of the mCAT1-positive cells. No
EGFP-positive cells were observed in non-transfected control
populations.
Transgene expression of selected lentivirus-transduced
pluripotent cells remains permanent in vitro and in vivo
We next asked whether transgene expression mediated by
lentiviral vectors remains permanent in selected hES cells,
thus overcoming the limitation of continuous drug selection
in the MoMuLV-transduced cells. To that end, pLentiPGK-
EGFP-SV40-blasticidine-transduced cells were plated on
matrigel 48 h after transduction and exposed to blasticidine
(4 mg/ml) for 3 days. Following this selection step, the cells
were continuously cultured on feeders (MEFs) for more
than 20 passages in the absence of blasticidine. At passage
20 post selection, lentivirus-transduced cells continued to
express markers of pluripotency (alkaline phosphatase,
Oct-4, Tra1-60 and Tra1-81) along with the EGFP transgene
(Figure 4C–F). To study stability of transgene expression
upon induction of differentiation, lentivirus-transduced cells
were aggregated to form EBs and cultured in the presence
of 5% FCS for 8 weeks. Upon plating, these EBs generated
an outgrowth of cells expressing EGFP as well as the
differentiation-associated markers cytokeratin, AFP and des-
min (Figure 4G–I). Maintenance of pluripotency of the
lentivirally transduced cells was further conﬁrmed by a ter-
atoma assay. To that end, 3 · 10
6 undifferentiated hES cells
from passage 20 post selection were injected into SCID-
beige mice. Nine weeks after injection, six out of eight
mice had developed teratomas exhibiting prominent EGFP-
expression (Figure 4J) and various different tissues including
adenoid tissue, epithelium and cartilage (Figure 4K and L).
DISCUSSION
Our results demonstrate that transient expression of the
murine retrovirus-receptor mCAT1 in hES cells permits per-
manent transduction by ecotropic retroviral vectors. This
method should provide signiﬁcant practical advantages and
enable applications, which go beyond those of conventional
lenti- and adenoviral transduction. First, the large number
of already established murine MoMuLV-derived vectors,
commonly available as supernatant from stable virus produc-
ing cell lines, can be directly applied to hES cells without
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unable to infect wild type human cells (7,33), transduction
of hES cells can be performed without the safety concerns
typically associated with the use of amphotropic vectors,
which may bear the risk of toxic effects for both recipient
and experimenter (8–10). The inability to infect normal
human cells should even permit the transduction of critical
vectors carrying immortalizing genes or active oncogenes
under standard safety conditions (33,34). Furthermore, the
two-step-protocol offers the possibility to restrict the viral
transduction by cell type-speciﬁc expression of the retrovirus
receptor. In murine systems, avian retrovirus receptors
have been used in this manner for cell type-speciﬁc gene
transfer (35–39), although the avian vectors have limitations
with respect to the transgene size. Whereas the CMV and
CAG promoter elements employed in this study are expected
to yield ubiquitous expression in a broad variety of cell
types, the use of suitable cell type-speciﬁc promoters should
permit targeted expression of the retrovirus receptor in
deﬁned cell lineages (40,41). Along these lines, our two-
step approach might be applied for the selection of speciﬁc
somatic lineages from differentiating hES cell cultures.
Finally, oncoretroviruses such as MoMuLV are particularly
suited for the study of progenitor cell populations because
they only infect dividing cells. This property has made
them a tool of choice for cell lineage analysis in many tissues
including the CNS (42,43). Thus, in addition to targeted gene
transfer, our system might be particularly useful for in vitro
clonal analyses of retrovirally labelled hES cell-derived
somatic stem cells and in vivo lineage tracing of transplanted
human cells (18,19).
A critical aspect in stem cell transduction is maintenance
of stem cell properties. Using bicistronic oncoretroviral
vectors carrying an antibiotic resistance gene, we selected
Figure 3. Retrovirally-transduced hES cells maintain transgene expression throughout neural differentiation. (A) Following discontinuation of G418 selection,
neurospheres derived from transduced hES continue to express EGFP across several passages. Shown are EGFP-expressing neurospheres cultured for 4 weeks
(five passages) without G418. (B) Following growth factor withdrawal, plated spheres show extensive neurite extension. (C–F) Plated neurospheres and single
cells derived thereof express the neuronal marker antigens beta-III-tubulin (C) and MAP2ab (D and E); astrocytes can be readily detected with an antibody to
GFAP (F). Both neurons and glial cells exhibit prominent EGFP expression. Scale bars: A–D: 100 mm; E and F: 20 mm.
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tion. The transduced clones maintained the expression of
pluripotency-associated markers and the ability to generate
derivatives of all three germ layers in vitro and in vivo.
Thus, the two-step-procedure involving transfection of the
mCAT1-receptor and subsequent retroviral transduction
appears not to interfere with the pluripotent properties of
ES cells.
A key challenge associated with the use of ecotropic retro-
viral vectors is the difﬁculty to obtain high-titer viral stocks.
The viral membrane is often very fragile and/or unstable,
making it difﬁcult to concentrate viral particles by collection
Figure 4. Pseudotyped lentiviral vectors enable efficient and permanent transduction of hES cells without selection pressure. (A and B) Ecotropic pseudotyped
lentiviral vectors efficiently transduce mCAT1 expressing hES cells. Forty-eight hours after transduction with concentrated virus supernatant, 27.2 ± 6.5% and
26.1 ± 7.2% of the total cell population transduced with pLentiPGK-EGFP-SV40-blasticidine (A) and pWPI expresses EGFP, respectively. Normalized to the
mCAT1 transfection rate, this corresponds to a calculated transduction rate of  50% of the mCAT1-transfected cells. (C–F) Selected pLentiPGK-EGFP-SV40-
basticidine-transduced cells continue to express markers of pluripotency. hES cells transduced by lentiviral vectors were selected via a blasticidine drug
resistance for three days and continuously cultured on feeders (MEFs) without further drug selection. Twenty passages after transduction the cells show sustained
expression of alkaline phosphatase (C, blue), Oct-4 (D), Tra-1-60 (E), and Tra-1-81 (F) (all red) while retaining high levels of transgene expression.
(G–J) Transgene expression is retained during germ layer differentiation in vitro. Twenty passages after transduction, lentivirally transduced cells were
aggregated to form EBs and continuously cultured in the presence of 5% FCS for 8 weeks. In the EB outgrowth, differentiation into derivatives of all three germ
layers could be detected. Cells expressing cytokeratin (G), alpha-feto-protein (H) and desmin (I) retain strong EGFP transgene expression. (J–L) Transgene
expression is retained after teratoma formation in vivo. Upon transduction and selection, 3 · 10
6 cells were injected into immunodeficient SCID-beige mice. Nine
weeks after injection, strongly EGFP-positive teratomas had formed (J). Teratomas contained various tissues including adenoid tissue (K), cartilage and
epithelium (L). Scale bars: A: 100 mm; C-F: 250 mm; G: 100 mm; H: 250 mm; I: 50 mm; J: 2,5 mm; K-L: 100 mm.
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study we have used low speed centrifugation over a period
of 12–16 h to concentrate the virus. We obtained titers of
up to 8.4 · 10
8 transducing units per ml for MMLV-based
vectors and up to 1.8 · 10
9 transducing units per ml for
lentiviral vectors which permitted efﬁcient infection of
mCAT1-expressing hES cells, thus providing a possible
solution to bypass restrictions by low titers of ecotropic
retroviruses.
Previous studies in mouse ES cells have shown that trans-
genes expressed from oncoretroviral vectors are rapidly
silenced upon differentiation (15,44–46). Consistent with
these observations we noticed a down-regulation of EGFP in
undifferentiated hES cells cultured over several passages,
and a rapid EGFP silencing in differentiating hES cell-derived
EBs. Down-regulation could be avoided by using a bicistronic
vector containing an IRES-linked resistance gene (neoR) and
maintenance of neomycin selection during differentiation.
hES cell cultures continuously propagated in the presence
of 150 mg/ml G418 maintained their proliferation rate as
well as their potential to generate EBs and derivatives of all
three germ layers. Interestingly, no further G418 treatment
was required once the cells had been shifted into a neural pre-
cursor state. HES cell-derived neural precursors proliferated
as neurospheres in FGF2 for at least 6 passages and subse-
quently differentiated for 6 weeks in the absence of growth
factors showed no obvious loss of EGFP expression. Thus,
our transduction system appears to be suitable for permanent
transgene expression in differentiated hES cell-derived pro-
geny, particularly in the neural lineage. It may, therefore,
also be applicable for in vivo lineage analysis of hES cell-
derived somatic cells. It should also be noted that the retroviral
construct used in our study carries a classic 50 LTR leader
sequence. These vectors are known to show a high frequency
of promoter silencing with low expression levels in ES and EC
cells (47). Constructs with different 50 LTR or 30 LTR leaders
such as the murine stem cell PCMV virus (MSCV), the murine
embryonic stem cell virus (MESV) or combinations thereof
have been tailored to applications in stem cell technology
and might be used to further enhance the efﬁciency of our
transduction system (11,48–51).
A critical parameter in assessing advantages and limita-
tions of viral gene transfer systems for hES cells is transduc-
tion efﬁciency. Using optimized transfection protocols and
concentrated oncoretroviral vectors, we achieved transduc-
tion rates of up to 20% of the total cell population, equaling
an estimated transduction efﬁciency of up to  40% of the
mCAT1-expressing cells. In comparison, direct transduction
of hES cells by lentiviral vectors pseudotyped with vesicular
stromatitis virus glycoprotein (VSV-G) yields transduction
efﬁciencies of 38–87% (52,53). These high transduction
rates have made lentiviral vectors an attractive tool for
gene transfer in stem cells and their progeny (53–67).
Lentiviral infection of hES cells has been shown to not affect
their pluripotent state and to yield stable transgene expression
upon germ layer differentiation (52–54). Recently, knock-
down strategies based on siRNA-expressing lentiviral vectors
have further kindled interest in this system (68–73). Consid-
ering these developments, we became interested in accom-
modating lentiviral vectors in our ecotropic transduction
paradigm. Using lentiviral vectors pseudotyped with the
ecotropic MoMuLV glycoprotein, we obtained transduction
efﬁciencies of up to 33% of the total cell population, equaling
an estimated transduction efﬁciency of up to  60% of the
mCAT1-expressing cells. Lentivirally transduced cells main-
tained expression of the transgene throughout proliferation
and differentiation without further selection pressure. Mainte-
nance of pluripotency was conﬁrmed by the co-expression of
pluripotency-associated markers in EGFP-positive transduced
hES cells and multi-germ layer differentiation in EGFP-
positive EBs derived thereof. Furthermore, lentivirally trans-
duced hES cells transplanted 20 passages after selection
formed teratomas with sustained EGFP expression. Thus,
our two-step protocol also enables lentivirus-based perma-
nent expression of transgenes in pluripotent hES cells under
standard safety precautions for murine ecotropic vectors.
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